Lenacapavir named 'breakthrough of the year' drug for HIV care

IN a step to fight against HIV/AIDS, the US Food and Drug Administration approved Lenacapavir, an injectable HIV drug.

- Kavita Bajeli-Datt

This drug protects people for six months with each shot. The Science journal has hailed the drug for its remarkable effectiveness in eliminating HIV infections, dubbing it as the 'breakthrough of the year'.

The publication said that the development marks a significant step to mitigate the impact of the global health crisis. Many researchers are now hopeful that the drug will drive down global infection rates when used as pre-exposure prophylaxis (PrEP), it said.